Ovarian Cancer Focus PROMISS Diagnostics has developed a non-invasive ovarian cancer diagnostic test designed to aid clinicians in early detection and improve patient outcomes while reducing costs. This creates a sales opportunity to partner with clinics, cancer centers, and hospital systems to adopt the test within existing diagnostic workflows.

Early Growth Opportunity With a small team and modest funding, PROMISS appears positioned to pursue scalable distribution and licensing deals rather than broad direct sales to maximize reach. Consider partnerships with contract laboratories or large diagnostics distributors to accelerate market penetration.

Strategic Partnerships Competitive landscape includes large, established players such as Invitae, Natera, Guardant Health, Quest Diagnostics, and others. This signals opportunities to license or co-develop PROMISS with a major player, or to offer integration through their lab networks and sales channels.

Regional Go-To-Market Based in Wisconsin with a Midwest footprint, the company could pilot the technology with regional hospitals and clinics to demonstrate value and generate case studies. Explore partnerships with regional health systems, insurers, and diagnostic networks to establish payer value and uptake.

Analytics and Tech The combination of basic science with advanced analytics positions PROMISS for data driven diagnostic tools and potential integration with laboratory information systems and electronic health records. This offers a sales angle centered on interoperability, data security, and value-based pricing tied to performance improvements.